Literature DB >> 25445206

Interferon regulatory factors: critical mediators of human lupus.

Mark A Jensen1, Timothy B Niewold2.   

Abstract

The pathogenesis of systemic lupus erythematosus (SLE) is multifactorial, and the interferon regulatory factors (IRFs) play an important role. Autoantibodies formed in SLE target nuclear antigens, and immune complexes formed by these antibodies contain nucleic acid. These immune complexes can activate antiviral pattern recognition receptors (PRRs), resulting in the downstream activation of IRFs, which can induce type I interferon (IFN-I) and other inflammatory mediators. Genetic variations in IRFs have been associated with susceptibility to SLE, and current evidence supports the idea that these polymorphisms are gain of function in humans. Recent studies suggest that these genetic variations contribute to the break in humoral tolerance that allows for nucleic acid binding autoantibodies, and that the same polymorphisms also augment IFN-I production in the presence of these autoantibody immune complexes, forming a feed-forward loop. In this review, we will outline major features of the PRR/IRF systems and describe the role of the IRFs in human SLE pathogenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25445206      PMCID: PMC4306637          DOI: 10.1016/j.trsl.2014.10.002

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  144 in total

Review 1.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

2.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.

Authors:  Robert R Graham; Sergey V Kozyrev; Emily C Baechler; M V Prasad Linga Reddy; Robert M Plenge; Jason W Bauer; Ward A Ortmann; Thearith Koeuth; Ma Francisca González Escribano; Bernardo Pons-Estel; Michelle Petri; Mark Daly; Peter K Gregersen; Javier Martín; David Altshuler; Timothy W Behrens; Marta E Alarcón-Riquelme
Journal:  Nat Genet       Date:  2006-04-16       Impact factor: 38.330

3.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus.

Authors:  A Perniok; F Wedekind; M Herrmann; C Specker; M Schneider
Journal:  Lupus       Date:  1998       Impact factor: 2.911

Review 5.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

6.  Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

Authors:  Silvia N Kariuki; Kyriakos A Kirou; Emma J MacDermott; Lilliana Barillas-Arias; Mary K Crow; Timothy B Niewold
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

8.  The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response.

Authors:  Kislay Parvatiyar; Zhiqiang Zhang; Rosane M Teles; Songying Ouyang; Yan Jiang; Shankar S Iyer; Shivam A Zaver; Mirjam Schenk; Shang Zeng; Wenwan Zhong; Zhi-Jie Liu; Robert L Modlin; Yong-jun Liu; Genhong Cheng
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

9.  Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production.

Authors:  Sharon A Chung; Kimberly E Taylor; Robert R Graham; Joanne Nititham; Annette T Lee; Ward A Ortmann; Chaim O Jacob; Marta E Alarcón-Riquelme; Betty P Tsao; John B Harley; Patrick M Gaffney; Kathy L Moser; Michelle Petri; F Yesim Demirci; M Ilyas Kamboh; Susan Manzi; Peter K Gregersen; Carl D Langefeld; Timothy W Behrens; Lindsey A Criswell
Journal:  PLoS Genet       Date:  2011-03-03       Impact factor: 5.917

Review 10.  Cytosolic sensing of viruses.

Authors:  Delphine Goubau; Safia Deddouche; Caetano Reis e Sousa
Journal:  Immunity       Date:  2013-05-23       Impact factor: 31.745

View more
  15 in total

Review 1.  Absent in Melanoma 2 proteins in SLE.

Authors:  Divaker Choubey; Ravichandran Panchanathan
Journal:  Clin Immunol       Date:  2017-01-03       Impact factor: 3.969

Review 2.  Updates in Lupus Genetics.

Authors:  Yun Deng; Betty P Tsao
Journal:  Curr Rheumatol Rep       Date:  2017-10-05       Impact factor: 4.592

Review 3.  Interferon regulatory factor signaling in autoimmune disease.

Authors:  Bharati Matta; Su Song; Dan Li; Betsy J Barnes
Journal:  Cytokine       Date:  2017-03-07       Impact factor: 3.861

Review 4.  Drugs in early clinical development for Systemic Lupus Erythematosus.

Authors:  Mariana Postal; Nailú Angélica Sinicato; Simone Appenzeller; Timothy B Niewold
Journal:  Expert Opin Investig Drugs       Date:  2016-04-07       Impact factor: 6.206

Review 5.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 6.  Immunogenetics of systemic lupus erythematosus: A comprehensive review.

Authors:  Yogita Ghodke-Puranik; Timothy B Niewold
Journal:  J Autoimmun       Date:  2015-08-29       Impact factor: 7.094

Review 7.  Advances in lupus genetics.

Authors:  Timothy B Niewold
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

Review 8.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

Review 9.  Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.

Authors:  Marilyn E Allen; Violeta Rus; Gregory L Szeto
Journal:  Trends Mol Med       Date:  2020-10-09       Impact factor: 11.951

10.  Autosomal Recessive ISG15 Deficiency Underlies Type I Interferonopathy with Systemic Lupus Erythematosus and Inflammatory Myositis.

Authors:  Sulaiman M Al-Mayouf; Lujayn Akbar; Abdullatif AlEnazi; Hamoud Al-Mousa
Journal:  J Clin Immunol       Date:  2021-03-19       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.